These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 25348227)

  • 1. Clarification on transdermal buprenorphine.
    Dankiewicz EH; Haddox JD
    J Pain Palliat Care Pharmacother; 2014 Dec; 28(4):415-6. PubMed ID: 25348227
    [No Abstract]   [Full Text] [Related]  

  • 2. Buprenorphine for chronic pain.
    Calderon R; Copenhaver D
    J Pain Palliat Care Pharmacother; 2013 Dec; 27(4):402-5. PubMed ID: 24245573
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Buprenorphine transdermal patch (Norspan tape)].
    Hamaguchi S; Ikeda T
    Masui; 2013 Jul; 62(7):799-807. PubMed ID: 23905402
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Buprenorphine 5, 10 and 20 μg/h transdermal patch: a guide to its use in chronic non-malignant pain.
    Plosker GL; Lyseng-Williamson KA
    CNS Drugs; 2012 Apr; 26(4):367-73. PubMed ID: 22369187
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Buprenorphine: revisiting the efficacy of transdermal delivery system.
    Kitzmiller JP; Barnett CJ; Steiner NS; Stoicea N; Kamar N; Luzum JA; Mikulik E; Bergese SD
    Ther Deliv; 2015; 6(4):419-22. PubMed ID: 25996041
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Transdermal buprenorphine (Butrans) for chronic pain.
    Med Lett Drugs Ther; 2011 Apr; 53(1362):31-2. PubMed ID: 21502936
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Understanding transdermal buprenorphine and a practical guide to its use for chronic cancer and non-cancer pain management.
    O'Brien T; Ahn JS; Chye R; Le B; Lu H; Olarte G; Palladini M; Salti A; Shao YY; Yaakup H; Buemio KC; Colin CG; Hadjiat Y
    J Opioid Manag; 2019; 15(2):147-158. PubMed ID: 31343716
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Opioid-induced functional esophagogastric junction obstruction.
    Sáez-González E; Díaz-Jaime FC; García-Morales N; Herreras-López J; Ortiz V; Ortuño J; Garrigues V
    Gastroenterol Hepatol; 2017 Apr; 40(4):296-298. PubMed ID: 26944440
    [No Abstract]   [Full Text] [Related]  

  • 9. The unique role of transdermal buprenorphine in the global chronic pain epidemic.
    Pergolizzi JV; Scholten W; Smith KJ; Leighton-Scott J; Willis JC; Henningfield JE
    Acta Anaesthesiol Taiwan; 2015 Jun; 53(2):71-6. PubMed ID: 26205326
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Switching from high doses of pure μ-opioid agonists to transdermal buprenorphine in patients with cancer: a feasibility study.
    Lundorff L; Sjøgren P; Hansen OB; Jonsson T; Nielsen PR; Christrup L
    J Opioid Manag; 2013; 9(4):255-62. PubMed ID: 24353018
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Retrospective analysis of 4 years of clinical experience with transdermal buprenorphine (Transtec) in post-traumatic pain.
    Correa-Illanes G; Roa RG; B Piñeros JL; Ferrer FT; Adriasola VR
    Pain Manag; 2014 May; 4(3):181-90. PubMed ID: 24835268
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and efficacy of transdermal buprenorphine and transdermal fentanyl in the treatment of neuropathic pain in AIDS patients.
    Canneti A; Luzi M; Di Marco P; Cannata F; Pasqualitto F; Spinoglio A; Reale C
    Minerva Anestesiol; 2013 Aug; 79(8):871-83. PubMed ID: 23558760
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effectiveness and tolerability of transdermal buprenorphine patches: a multicenter, prospective, open-label study in Asian patients with moderate to severe chronic musculoskeletal pain.
    Yoon DH; Bin SI; Chan SK; Chung CK; In Y; Kim H; Lichauco JJ; Mok CC; Moon YW; Ng TK; Penserga EG; Shin DA; You D; Moon H
    BMC Musculoskelet Disord; 2017 Aug; 18(1):337. PubMed ID: 28778219
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Buprenorphine.
    Foster B; Twycross R; Mihalyo M; Wilcock A
    J Pain Symptom Manage; 2013 May; 45(5):939-49. PubMed ID: 23648060
    [No Abstract]   [Full Text] [Related]  

  • 15. Transdermal buprenorphine for the treatment of moderate to severe chronic pain: results from a large multicenter, non-interventional post-marketing study in Poland.
    Przeklasa-Muszynska A; Dobrogowski J
    Curr Med Res Opin; 2011 Jun; 27(6):1109-17. PubMed ID: 21456888
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of buprenorphine transdermal system (BTDS) for chronic moderate to severe low back pain: a randomized, double-blind study.
    Steiner D; Munera C; Hale M; Ripa S; Landau C
    J Pain; 2011 Nov; 12(11):1163-73. PubMed ID: 21807566
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Transdermal buprenorphine and silent acute coronary syndrome].
    Vidal MA; Calderón E; Pernia A; Calderón-Pla E; Torres LM
    Rev Esp Anestesiol Reanim; 2006 Jan; 53(1):58-9. PubMed ID: 16475644
    [No Abstract]   [Full Text] [Related]  

  • 18. Comparison of abuse, suspected suicidal intent, and fatalities related to the 7-day buprenorphine transdermal patch versus other opioid analgesics in the National Poison Data System.
    Coplan PM; Sessler NE; Harikrishnan V; Singh R; Perkel C
    Postgrad Med; 2017 Jan; 129(1):55-61. PubMed ID: 27922764
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Buprenorphine transdermal system and quality of life in opioid-experienced patients with chronic low back pain.
    Miller K; Yarlas A; Wen W; Dain B; Lynch SY; Brennan MJ; Ripa SR
    Expert Opin Pharmacother; 2013 Feb; 14(3):269-77. PubMed ID: 23374027
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Buprenorphine buccal film (Belbuca) for chronic pain.
    Med Lett Drugs Ther; 2016 Apr; 58(1492):47-8. PubMed ID: 27049508
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.